Reach Us +1 850 900 2634

International Journal of Cardiovascular ResearchISSN: 2324-8602

Aliskiren: Is Combination Therapy with Angiotensin Converting Enzyme Inhibitors(ACE-I) or Angiotensin Receptor Blockers (ARBS) still a Possibility?

Aliskiren: Is Combination Therapy with Angiotensin Converting Enzyme Inhibitors(ACE-I) or Angiotensin Receptor Blockers (ARBS) still a Possibility?

Aliskiren is a blood pressure-lowering agent, which is the first representative of a class of orally active renin inhibitors that directly blocks the Renin-Angiotensin-Aldosterone-System (RAAS) at its rate limiting step. Aliskiren reduces blood pressure by direct renin inhibition and causes a net reduction in plasma renin activity, angiotensin II and aldosterone levels. Aliskiren is marketed in Canada by Novartis under the trade name Rasilez.Until recently, aliskiren has been used in combination with angiotensin converting enzyme inhibitor (ACE-I) or angiotensin receptor blockers (ARBs) to reduce blood pressure to target values via a synergistic blockade of the reninangiotensin system (RAS).

Special Features

Full Text

View

Track Your Manuscript

Share This Page

Media Partners

Associations